The field of cardiac cell therapy is under siege. Legacies of excessive hype, scientific misconduct and dead ends have fuelled the prevailing scepticism. However, promising clinical data, along with more trenchant mechanistic understanding, together provide glimmers of hope for the future of cell therapy for the heart.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marban, E. A mechanistic roadmap for the clinical application of cardiac cell therapies. Nat. Biomed. Eng. 2, 353–361 (2018).
Mathur, A. et al. The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction: The Bami Trial. Eur. Heart J. 41, 3702–3710 (2020).
Vagnozzi, R. J. et al. An acute immune response underlies the benefit of cardiac stem cell therapy. Nature 577, 405–409 (2020).
Vagnozzi, R. J. et al. Cardiac cell therapy rejuvenates the infarcted rodent heart via direct injection but not by vascular infusion. Circulation 141, 1037–1039 (2020).
Vagnozzi, R. J. et al. Cardiac cell therapy fails to rejuvenate the chronically scarred rodent heart. Circulation 144, 328–331 (2021).
Ibrahim, A. G. et al. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2, 606–619 (2014).
Rogers, R. G. et al. Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in Mdx mice. JCI Insight 4, e125754 (2019).
Taylor, M. et al. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne Trial. Neurology 92, e866–e878 (2019).
Aminzadeh, M. A. et al. Exosome-mediated benefits of cell therapy in mouse and human models of duchenne muscular dystrophy. Stem Cell Reports 10, 942–955 (2018).
Marban, L. et al. Late breaking news e-poster presentation: LBP 5 HOPE-2 one-year results show clinically relevant improvements in upper limb &cardiac function in patients with later stage Duchenne Muscular Dystrophy. Neuromuscul. Disord. 30, S168–S169 (2020).
Acknowledgements
The author is supported by funding from the NIH and the US Department of Defense.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author owns founder’s equity in Capricor Therapeutics.
Rights and permissions
About this article
Cite this article
Marbán, E. A phoenix rises from the ashes of cardiac cell therapy. Nat Rev Cardiol 18, 743–744 (2021). https://doi.org/10.1038/s41569-021-00625-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-021-00625-1
This article is cited by
-
On the cellular origin of cardiosphere-derived cells (CDCs)
Basic Research in Cardiology (2022)